Horizon / Plein textes La base de ressources documentaires de l'IRD

IRD

 

Publications des scientifiques de l'IRD

Beaudrap Pierre de, Thiam M., Diouf A., Toure-Kane C., Ngom-Gueye N.F., Vidal Nicole, Mboup S., Ndoye I., Sow P.S., Delaporte Eric. (2013). Risk of virological failure and drug resistance during first and second-line antiretroviral therapy in a 10-year cohort in Senegal : results from the anrs 1215 cohort. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 62 (4), 381-387. ISSN 1525-4135

Accès réservé (Intranet IRD) Demander le PDF

Lien direct chez l'éditeur doi:10.1097/QAI.0b013e31827a2a7a

Titre
Risk of virological failure and drug resistance during first and second-line antiretroviral therapy in a 10-year cohort in Senegal : results from the anrs 1215 cohort
Année de publication2013
Type de documentArticle référencé dans le Web of Science WOS:000319037700008
AuteursBeaudrap Pierre de, Thiam M., Diouf A., Toure-Kane C., Ngom-Gueye N.F., Vidal Nicole, Mboup S., Ndoye I., Sow P.S., Delaporte Eric.
SourceJAIDS-Journal of Acquired Immune Deficiency Syndromes, 2013, 62 (4), p. 381-387. ISSN 1525-4135
RésuméBackground: In 1998, Senegal launched one of Africa's first anti-retroviral therapy (ART) programs. Since then, the number of treated patients in Africa has substantially increased thanks to simplification in treatment management. Although good outcomes over the first years of ART have been observed in sub-Saharan Africa, little is known about the long-term (>5 years) risks of virological failure and drug resistance and about second-line treatment response. Methods: Patients from the ANRS-1215 cohort in Senegal, started with either one nonnucleoside reverse transcriptase inhibitor or indinavir, a first-generation nonboosted protease inhibitor, followed for >6 months and having >1 viral load (VL) measurement were included. Virological failure was defined as 2 consecutive VL measurements >1000 copies/mL. Results: Of the 366 patients included, 89% achieved a VL <500 copies/mL. The risk of virological failure at 12, 24, and 60 months was 5%, 16%, and 25%, being higher in younger patients (P = 0.05), those receiving a protease inhibitor-containing regimen (P = 0.05), and those with lower adherence (P = 0.03). The risk of resistance to any drug at 12, 24, and 60 months was 3%, 11%, and 18%. After virological failure, 60% of the patients were switched to second-line treatments. Although 81% of the patients achieved virological success, the risk of virological failure was 27% at 24 months, mostly in patients with multiple resistances. Conclusions: In this cohort, virological outcomes for first-line treatments were good compared with those from high-resource settings. However, the rate of virological failure for second-line treatment was high, probably because of accumulation of resistances.
Plan de classementEntomologie médicale / Parasitologie / Virologie [052] ; Santé : généralités [050]
Descr. géo.SENEGAL ; AFRIQUE SUBSAHARIENNE
LocalisationFonds IRD [F B010060353]
Identifiant IRDfdi:010060353
Lien permanenthttp://www.documentation.ird.fr/hor/fdi:010060353

Export des données

Disponibilité des documents

Télechargment fichier PDF téléchargeable

Lien sur le Web lien chez l'éditeur

Accès réservé en accès réservé

HAL en libre accès sur HAL


Accès aux documents originaux :

Le FDI est labellisé CollEx

Accès direct

Bureau du chercheur

Site de la documentation

Espace intranet IST (accès réservé)

Suivi des publications IRD (accès réservé)

Mentions légales

Services Horizon

Poser une question

Consulter l'aide en ligne

Déposer une publication (accès réservé)

S'abonner au flux RSS

Voir les tableaux chronologiques et thématiques

Centres de documentation

Bondy

Montpellier (centre IRD)

Montpellier (MSE)

Cayenne

Nouméa

Papeete

Abidjan

Dakar

Niamey

Ouagadougou

Tunis

La Paz

Quito